Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 10, 2012. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 590,000 Ordinary Shares of 25 pence each.
- Purchase Date: December 10, 2012.
- Price Range: Highest price paid was 1,365.5 pence per share; lowest price paid was 1,346 pence per share.
- Treasury Holdings (Settled): 490,831,227 shares (9.09% of total issued share capital).
- Treasury Holdings (Including Unsettled): 492,796,327 shares (10.04% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,906,351,036 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 590,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior level to 10.04% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (490,831,227 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights (10.04% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Check the remaining authorization for share buybacks under the May 3, 2012 shareholder mandate.
- Review the settlement status of the 1,965,100 shares included in the "unsettled" count to determine final Treasury holdings.